Weighty problems
THE Medicines and Healthcare products Regulatory Agency (MHRA) is to study possible serious side effects of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro).
There have been 574 reported reactions of acute and chronic pancreatitis from the time of the drugs’ licensing until 13 May 2025, of which 10 cases were fatal (although it’s not certain the drugs were the cause). All drugs have harms as well as benefits, and for new drugs it can take years for the true picture to emerge.